BTTX insider filings
Better Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-02-13. Screen BTTX transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for BTTX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Better Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-02-13 | 4 | PERRY DAVID P — Executive Chairman, Director, 10% owner David P. Perry 2015 Trust — 10% owner | Grant/award (A): 839,895 @ $0.19 | EDGAR |
| 2024-01-10 | 4 | PERRY DAVID P — Executive Chairman, Director, 10% owner | Grant/award (A): 1,471,453 @ $0.17 | EDGAR |
| 2023-12-20 | 4 | Wynholds Kristin — Chief Product Officer | Grant/award (A): 25,362 @ $0 | EDGAR |
| 2023-12-20 | 4 | Miller Leslie A. — Principal Accounting Officer | Grant/award (A): 3,587 @ $0 | EDGAR |
| 2023-12-20 | 4 | Berman Mark A. — Chief Medical Officer | Grant/award (A): 25,362 @ $0 | EDGAR |
| 2023-12-20 | 4 | Armanino Andrew J. — Director | Grant/award (A): 3,750 @ $0 | EDGAR |
| 2023-12-20 | 4 | Granger Elder — Director | Grant/award (A): 3,750 @ $0 | EDGAR |
| 2023-12-20 | 4 | Parker Geoffrey M. — Director | Grant/award (A): 3,750 @ $0 | EDGAR |
| 2023-12-20 | 4 | Carmona Richard H — Director | Grant/award (A): 3,750 @ $0 | EDGAR |
| 2023-12-20 | 4 | KARBE FRANK — Chief Executive Officer, Director | Grant/award (A): 62,500 @ $0 | EDGAR |
| 2023-12-20 | 4 | PERRY DAVID P — Executive Chairman, Director, 10% owner | Grant/award (A): 3,750 @ $0 | EDGAR |
| 2023-12-20 | 4 | LAVIZZO-MOUREY RISA J — Director | Grant/award (A): 3,750 @ $0 | EDGAR |
| 2023-07-31 | 4 | Berman Mark A. — Chief Medical Officer | Purchase (P): 54,802 @ $0.73 | EDGAR |
| 2023-07-31 | 4 | Armanino Andrew J. — Director | Purchase (P): 274,010 @ $0.73 | EDGAR |
| 2023-07-31 | 4 | Granger Elder — Director | Purchase (P): 34,251 @ $0.73 | EDGAR |
| 2023-07-31 | 4 | Parker Geoffrey M. — Director | Purchase (P): 685,025 @ $0.73 | EDGAR |
| 2023-07-31 | 4 | KARBE FRANK — Chief Executive Officer, Director | Purchase (P): 137,005 @ $0.73 | EDGAR |
| 2023-07-31 | 4 | PERRY DAVID P — Executive Chairman, Director, 10% owner | Purchase (P): 1,233,045 @ $0.73 | EDGAR |
| 2023-06-09 | 4 | Armanino Andrew J. — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Granger Elder — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Parker Geoffrey M. — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Carmona Richard H — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | PERRY DAVID P — Executive Chairman, Director, 10% owner | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | LAVIZZO-MOUREY RISA J — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2023-05-18 | 4 | Granger Elder — Director | Purchase (P): 600 @ $0.87 | EDGAR |
| 2023-04-21 | 4 | Heinen Mark — Chief Financial Officer | Grant/award (A): 54,000 @ $0 · Grant/award (A): 28,550 (derivative) @ $0 | EDGAR |
| 2023-04-21 | 4 | Wynholds Kristin — Chief Product Officer | Grant/award (A): 101,450 @ $0 · Grant/award (A): 101,450 (derivative) @ $0 | EDGAR |
| 2023-04-21 | 4 | Berman Mark A. — Chief Medical Officer | Grant/award (A): 101,450 @ $0 · Grant/award (A): 101,450 (derivative) @ $0 | EDGAR |
| 2023-04-12 | 4 | Armanino Andrew J. — Director | Purchase (P): 303,030 @ $0.82 | EDGAR |
| 2023-04-12 | 4 | Parker Geoffrey M. — Director | Purchase (P): 303,030 @ $0.82 | EDGAR |
| 2023-04-12 | 4 | KARBE FRANK — See Remarks, Director | Purchase (P): 242,424 @ $0.82 | EDGAR |
| 2023-04-12 | 4 | PERRY DAVID P — See Remarks, Director, 10% owner David P. Perry 2015 Trust — 10% owner | Purchase (P): 1,333,333 @ $0.82 · Purchase (P): 3,636,364 @ $0.82 | EDGAR |
| 2022-12-02 | 4 | Wynholds Kristin — Chief Product Officer | Grant/award (A): 5,023 @ $1.54 · Grant/award (A): 3,781 @ $1.24 | EDGAR |
| 2022-12-02 | 4 | Heinen Mark — See Remarks | Grant/award (A): 15,723 @ $1.24 | EDGAR |
| 2022-09-19 | 4 | PERRY DAVID P — See Remarks, Director, 10% owner David P. Perry 2015 Trust — 10% owner | Purchase (P): 10,844 @ $1.99 · Purchase (P): 39,156 @ $2.07 | EDGAR |
| 2022-09-15 | 4 | KARBE FRANK — See Remarks, Director | Purchase (P): 50,000 @ $2.09 | EDGAR |
| 2022-09-14 | 4 | Heinen Mark — See Remarks | Purchase (P): 23,868 @ $1.94 · Purchase (P): 26,132 @ $1.94 | EDGAR |
| 2022-07-07 | 4 | KARBE FRANK — See Remarks, Director | Grant/award (A): 472,200 (derivative) @ $0 | EDGAR |
| 2022-06-28 | 4 | Heinen Mark — See Remarks | Purchase (P): 2,280.61 @ $1.75 | EDGAR |
| 2022-06-16 | 4 | Armanino Andrew J. — Director | Purchase (P): 15,000 @ $1.39 | EDGAR |
| 2022-06-14 | 4 | Parker Geoffrey M. — Director | Purchase (P): 25,000 @ $1.45 | EDGAR |
| 2022-06-10 | 4 | Heinen Mark — See Remarks | Purchase (P): 5,000 @ $1.56 | EDGAR |
| 2022-06-10 | 4 | Liu Suying — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Armanino Andrew J. — Director | Purchase (P): 25,000 @ $1.65 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Granger Elder — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Parker Geoffrey M. — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Carmona Richard H — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | PERRY DAVID P — See Remarks, Director, 10% owner | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | LAVIZZO-MOUREY RISA J — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2022-06-01 | 4 | Zamirowski Justin — Chief Commercial Officer | Option exercise (M): 1,677 @ $0.50 · Option exercise (M): 1,677 (derivative) @ $0 | EDGAR |
Recent 8-K events — Better Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2024-03-21 | 8-K | 2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement | EDGAR |
| 2024-03-15 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2024-03-14 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-03-11 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-03-04 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-01-08 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-12-18 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2023-12-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-11-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events | EDGAR |
| 2023-11-20 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BTTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs